|
 |
Nome commerciale |
|
|
Trade names are indicative and excipients composition can be different depending on the country and manufacturers
|
|
Camtoop |
Messico |
|
Cantop |
India |
|
Hycamtin |
Arabia Saudita, Australia, Austria, Belgio, Brasile, Canada, Chile, Colombia, Croazia, Danimarca, Egitto, Emirati Arabi Uniti, Finlandia, Francia, Germania, Giappone, Gran Bretagna, Grecia, Irlanda, Islanda, Italia, Lussemburgo, Malaysia, Norvegia, Paesi Bassi, Polonia, Portogallo, Romania, Spagna, Stati Uniti d’America, Svezia, Svizzera, Turchia, Ungheria, Venezuela |
|
Oncotecan |
Colombia, Ecuador |
|
Potactasol |
Argentina, Belgio, Croazia, Finlandia, Germania, Irlanda, Italia, Norvegia, Romania, Slovenia, Ungheria |
|
Topodria |
Colombia |
|
Topokebir |
Argentina |
|
Topotecan |
Argentina, Belgio, Brasile, Canada, Chile, Colombia, Croazia, Finlandia, Francia, Germania, Gran Bretagna, Irlanda, Italia, Norvegia, Perù, Romania, Spagna, Svezia, Svizzera, Ungheria |
|
Topotel |
Egitto |
|
Toranex |
Messico |
|
Tpopoxin |
Turchia |
|
|
 |
 |
Bibliografia : Topotecan |
|
|
tipo |
pubblicazione |
| 753 |
Laboratorio |
Topotecan (Topotecan Medac®) - Summary of Product Characteristics
Medac 2016 |
| 823 |
Rivista |
Patel K, Craig SB, McBride MG, Palepu NR.
Microbial inhibitory properties and stability of topotecan hydrochloride injection.
Am J Health-Syst Pharm 1998 ; 55: 1584-1587. |
| 1026 |
Rivista |
Mayron D, Gennaro AR.
Stability and compatibility of topotecan hydrochloride with selected drugs.
Am J Health-Syst Pharm 1999 ; 56: 875-881. |
| 1075 |
Rivista |
Craig SB, Bhatt UH, Patel K.
Stability and compatibility of topotecan hydrochloride for injection with common infusion solutions and containers.
J Pharm Biomed Anal 1997 ; 16: 199-205. |
| 1274 |
Rivista |
Krämer I, Thiesen J.
Pharmazeutische aspekte von topotecan-infusionen.
TAP Pharmazeutische Zeitung 1997 ; 31: 30-33. |
| 1423 |
Rivista |
Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518. |
| 1425 |
Rivista |
Krämer I, Thiesen J.
Stability of topotecan infusion solutions in polyvinylchloride bags and elastomeric portable infusion devices.
J Oncol Pharm Practice 1999 ; 5: 75-82. |
| 1662 |
Rivista |
Trissel LA, Saenz CA, Ingram DS, Ogundele AB.
Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs.
J Oncol Pharm Practice 2002 ; 8: 33-37. |
| 1953 |
Rivista |
Trissel LA, Saenz CA, Ogundele AB, Ingram DS.
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 2289-2293. |
| 1976 |
Rivista |
Trissel LA, Xu QA.
Physical and chemical stability of palonosetron hydrochloride with topotecan hydrochloride and irinotecan hydrochloride during simulated Y-site administration.
Int J Pharm Compound 2005 ; 9, 3: 238-241. |
| 5157 |
Rivista |
Bello W, Hosotte C, Stampfli C, Pierrot A, Munier F L, Berger-Gryllaki M, Pezzatti J, Carrez L, Sadeghipour F.
Stability study of topotecan in ophthalmic prefilled syringes for intravitreal delivery
EJHP 2025 33:67-72 |
|
|
